TOPIC 429 - A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING (SBIR)

Proteios Technology开发了一种专有平台，不依赖抗体或磁珠来分离细胞亚群。该平台已经在使用CD4+和CD8+亚群的T细胞上进行了验证，用于生产自体CAR-T细胞疗法。他们目前正在扩展自然杀伤（NK）细胞的分离平台，用于生产自体CAR-NK细胞疗法和同种异体NK细胞疗法。该提案的第一阶段将允许Proteios构建一个实验原型，以验证其生产CAR-T细胞疗法的平台的规模，并对当前的制造方法进行基准测试。Proteios的模块化方法将提供灵活性，以适应新的细胞治疗方法，因为研究人员能够用他们的研究仪器分离新的细胞亚群。Proteios的愿景是继续构建大规模的cGMP原型，并应用他们的技术来帮助降低医疗保健疗法的成本，包括细胞疗法和基因疗法。

Proteios Technology has developed a proprietary platform that does not rely on antibodies nor magnetic beads to isolate cell subpopulations. The platform has been validated on T cells using the CD4+ and CD8+ subpopulations for the production of autologous CAR-T cell therapies. They are currently extending the platform for the isolation of Natural Killer (NK) cells for the production of autologous CAR-NK cell therapies and allogeneic NK cell therapies. Phase I of the proposal will allow Proteios to construct a bench prototype to validate the scale-up of their platform for the production of CAR-T cell therapies and for benchmarking against current manufacturing methods. Proteios’ modular approach will provide the flexibility to adapt to new approaches to cell therapies as researchers are able to isolate new cell subpopulations with their research instrument. Proteios’ vision is to move on to construct an at-scale cGMP prototype and apply their technologies to help lower the cost of healthcare therapies, including cell therapies and gene therapies.